U

nder pressure to appease investors, Sanofi (SNY) has twice in the past week agreed to pay hefty amounts of money to buy a pair of companies that specialize in treating blood disorders. In doing so, the drug maker is scrambling to remake itself as its key diabetes franchise struggles under pricing pressure.

The latest deal involves paying more than $4.8 billion for Ablynx (ABLYF), which is researching rare blood disorders and developing novel drugs based on so-called nanobodies that are found in the immune systems of llamas and alpacas. Just last week, the drug maker paid agreed to pay $11.6 billion for Bioverativ (BIVV) — and a pair of hemophilia treatments — that was spun off by Biogen (BIIB).

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy